Study reveals how inflammatory immune cells enhance prostate cancer resistance

There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully understood. A new study by the University of Eastern Finland found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus immune to treatment. The results were published in OncoImmunology journal.

The image shows prostate cancer cells in which KLF4 (red) and the CD44 protein (green) on the cell membrane are stained. Image: Kirsi Kainulainen, University of Eastern Finland, Institute of Biomedicine

The study examined the impact of factors promoting inflammation in a tumor microenvironment on the progression of prostate cancer. Researchers focused particularly on the role of M1 and M2 macrophages in the tumor microenvironment. Macrophages are immune cells whose large number in the tumor area is often a sign of poor prognosis in relation to prostate cancer. The study found that pro- inflammatory macrophages (M1) increase the stem cell traits of cancer cells and weaken the androgen response.

We found that pro-inflammatory M1 macrophages secreted factors that increased the expression of stem cell markers such as NANOG, KLF4, SOX2 and CD44 in prostate cancer cells. Based on our research, it seems that inflammatory tumor microenvironment promotes the transformation of prostate cancer cells into a stem cell-like state where they are resistant to traditional therapies."

Kirsi Kainulainen, Doctoral Researcher 

The results help us understand how immune response affects the progression of prostate cancer and resistance to treatments. Observations on the effects of immune cells on the transformation capacity of cancer cells may open up new treatment opportunities for prostate cancer.

The study was carried out by Senior University Lecturer Sanna Pasonen- Seppänen and Research Director Kirsi Ketola at the University of Eastern Finland's Institute of Biomedicine. The study has been supported by the Academy of Finland, the Sigrid Juselius Foundation, the Cancer Foundation Finland, the North Savo Cancer Association, the Finnish Cultural Foundation, the Northern Savo Cultural Foundation, the Paavo Koistinen Foundation and the Kuopio University Foundation.

Source:
Journal reference:

Kainulainen, K., et al. (2024) Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2, and CD44 through NFκB-signaling. Oncoimmunology. doi.org/10.1080/2162402X.2024.2393442.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Post-treatment lifestyle choices influence long-term outcomes in breast cancer patients